Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Biopub link?

<< Previous

Bullboard Posts

Next >>

Comment by rico91on Apr 04, 2021 5:31pm

126 Views

Post# 32935437

RE:RE:Biopub link?

Thanks for the response. I have listened to a number of these chats and am surprised that this one would be private. I would hope that nothing that we don't already know was discussed or released.
I would expect that we will hear from Chris early next week as we have not had any commentary from him other than the official release.
We are all very disappointed with the announcement as such. I already had my Caribbean condo picked out, but alas...
We may or may not be done here, but I would like to hear more from the company.
glto
Rico

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages